Amplia Therapeutics Reports Four Additional Complete Responses and Improved Survival in ACCENT Pancreatic Cancer Trial

on

Independent central analysis of 64 patients in the ACCENT Phase 1b/2a trial confirmed five complete responses (7.8% rate) with 400mg narmafotinib plus gemcitabine/Abraxane chemotherapy123

Median overall survival of 11.1 months, improving ~2 months over gemcitabine-Abraxane standard (MPACT:
8.5 months)12

Objective response rate of 35.9% (23/64 patients), exceeding MPACT's 23%123

Four additional complete responses identified beyond initial reports, verified by RECIST 1.1 criteria12

Data selected for presentation at AACR conference in April 2026; four patients still on study as of March 15, 2026, one nearing 24 months12

Sources:

1. https://stockwirex.com/asx-stock-news/biotech-health/atx-amplia-therapeutics-accent-trial-results-march-2026/

2. https://investingnews.com/amplia-therapeutics-reports-four-additional-complete-responses-and-improved-overall-survival-data-in-accent-pancreatic-cancer-trial/

3. https://smallcaps.com.au/article/amplia-therapeutics-reports-stronger-efficacy-and-survival-in-pancreatic-cancer-trial